The effects of formulation on the pharmacokinetics of itraconazole and amiodarone in dogs after oral administration of a combination product, commercial products, and compounded products
Journal of Veterinary Pharmacology and Therapeutics · 2024
DOI: 10.1111/jvp.13411 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Veterinary Pharmacology and Therapeutics, 2024. Verfasst von Robert P Hunter und 1 weiteren Autor:innen. Beteiligte Einrichtung: One Medicine Consulting, Olathe, Kansas, USA. Hauptthemen laut MEDLINE: Itraconazole. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
This study evaluated four different formulations of itraconazole and amiodarone. Formulation 1 was Vida's combination tablet containing both active pharmaceutical ingredients (APIs). Formulation 2 was separate, commercially available human generic capsules and tablets of itraconazole and amiodarone, respectively. Formulation 3 was separate, compounded suspensions of itraconazole and amiodarone. Formulation 4 was a compounded chewable tablet of itraconazole. Eight female dogs were dosed with 5 mg/kg of itraconazole and 15 mg/kg amiodarone (except for formulation 4, which only received 5 mg/kg itraconazole) once weekly for 4 weeks using a modified Latin Square design, ensuring that all dogs received all formulations with a 7‐day washout between treatments. Animals were fasted overnight prior to each dose administration, with food returned to all animals 4 h post‐dose. Blood samples (3 mL) were collected pre‐treatment (0) and at appropriate time points over 72 h after each dose for a total of 14 samples per dog per treatment. There was high variability in the serum concentration data within treatment groups for itraconazole. The compounded suspensions were difficult to dose due to the nature of the formulations. The volumes dosed were accurate and consistent, but the suspension was thin and settled immediately when shaking was stopped for both itraconazole and amiodarone. All serum samples following itraconazole chewable tablet administration were not detectable or just above itraconazole's LOQ and thus did not allow for pharmacokinetic determination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- One Medicine Consulting, Olathe, Kansas, USA.
- Vida Pharmacal, Inc., Spring Branch, Texas, USA.
ORCID-Profile: Robert P Hunter
Zitieren
APA
Hunter, R. P., & Madigan, R. (2024). The effects of formulation on the pharmacokinetics of itraconazole and amiodarone in dogs after oral administration of a combination product, commercial products, and compounded products. Journal of Veterinary Pharmacology and Therapeutics. https://doi.org/10.1111/jvp.13411
Vancouver
Hunter RP, Madigan R. The effects of formulation on the pharmacokinetics of itraconazole and amiodarone in dogs after oral administration of a combination product, commercial products, and compounded products. Journal of Veterinary Pharmacology and Therapeutics. 2024. doi:10.1111/jvp.13411
BibTeX
@article{Hunter2024,
author = {Hunter, Robert P and Madigan, Roy},
title = {The effects of formulation on the pharmacokinetics of itraconazole and amiodarone in dogs after oral administration of a combination product, commercial products, and compounded products},
journal = {Journal of Veterinary Pharmacology and Therapeutics},
year = {2024},
doi = {10.1111/jvp.13411}
}
EUVIMED